Dupilumab in atopic dermatitis, a protocol for
            <scp>SARS‐COV‐</scp>
            2‐infected patients

Rubiano, María Fernanda Ordóñez; Campo, Isabela; Casas, Mirian

doi:10.1111/dth.14172

Cited by 8 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 22-year-old male patient was diagnosed with asymptomatic SARS-CoV-2 infection. 38 Later, the same authors described another COVID-19 case in a young adult (27 years old) patient on dupilumab, who was also HIV-positive. Like in the previous publication, these authors did not provide a detailed clinical description, but his clinical course was reported to be mild and without need of hospitalization.…”

Section: Dupilumabmentioning

confidence: 98%

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Poddighe¹,

Kovzel²

2021

JIR

View full text Add to dashboard Cite

SARS-CoV-2 pandemic had a general and deep impact on the clinical management of chronic diseases, including respiratory and allergic disorders. At the beginning of the pandemic, one of the main concerns was the potential impact of immunosuppressive/immunomodulatory drugs on COVID-19 clinical course. In this review, we aim to summarize and analyze the available clinical evidence from patients treated with anti-type 2 inflammation biologics (including anti-IgE, anti-IL-5 and anti-IL-4 agents), who developed COVID-19. Overall, the treatment with anti-Th2 biologics can be considered safe during COVID-19. It does not worsen the clinical course and outcome of COVID-19, and it may be actually protective somehow from developing severe forms. Moreover, patients treated with these biological agents do not seem to be more prone to get infected by SARS-CoV-2.

show abstract

Section: Dupilumabmentioning

confidence: 98%

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Poddighe¹,

Kovzel²

2021

JIR

View full text Add to dashboard Cite

show abstract

“…We found additional two papers by manual search trials (Figure 1 ). 1 , 2 , 9 , 10 , 12 , 13 , 19 , 20 , 21 , 22 , 23 , 24 …”

Section: Resultsmentioning

confidence: 99%

“…We found additional two papers by manual search trials (Figure 1). 1,2,9,10,12,13,[19][20][21][22][23][24] Five cross-sectional studies, two retrospective cohorts, two case series and three case reports (Table 1) with a total sample size of 1611 patients were included. Seven studies were conducted in Italy and the remaining studies were conducted in United States,…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients

El‐Qushayri

Mahmoud

Salman

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

The aim of this meta‐analysis is to evaluate the safety of dupilumab use in the management of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of COVID‐19 infection. Seven databases (Google Scholar, Web of Science, Scopus, Virtual Health Library, PubMed, System for Information on Gray Literature in Europe, and The New York Academy of Medicine) were searched for eligible studies from inception until November 24, 2021. The quality of evidence was rated using the National Institute of Health and the Joanna Briggs Institute Critical Appraisal tool. Meta‐analysis was performed when the outcome is presented ≥2 studies. A total of 12 papers including 1611 AD patients were included in the study. The prevalence of COVID‐19 in AD treated with dupilumab was 3.2% (95% confidence interval [CI]: 1.7–5.8). COVID‐19 symptoms were reported by five patients who were presented with one or more of the following symptoms (fatigue, loss of taste and smell, runny nose, conjunctivitis, gastrointestinal symptoms, fever, cough, and dyspnea). Only three cases of COVID‐19 were hospitalized with a prevalence of 4.5%, while no patients with COVID‐19 died. Dupilumab is safe regarding the risk and the hazards of COVID‐19 in AD patients. Thus, based on these results continuation of dupilumab in AD patients is recommended, since dupilumab seems to be safe and crucial for a better disease outcome.

show abstract

“…These differences could be related to the point in time of the COVID-19 pandemic, as in due course more knowledge about the infection was gained and patients felt more reassured to continue with their treatment. Ordóñez-Rubiano et al 13 presented a protocol for dupilumab-treated patients with AD that suggested that treatment should be stopped only in symptomatic COVID-19 patients requiring intensive care. Our patients, who were young and without risk factors of severe COVID-19, had a mild disease course.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review

Ceryn¹,

Niedźwiedź²,

Skibińska³

et al. 2021

CCID

View full text Add to dashboard Cite

There are limited clinical data on the impact of the SARS-CoV2 infection on patients with dermatological conditions treated with biologics. Dupilumab is a recombinant human IgG 4 human monoclonal antibody that inhibits IL4 and IL13 signaling, and is used for moderate–severe atopic dermatitis treatment. We present three patients with atopic dermatitis (AD) treated with dupilumab who contracted COVID-19. In all patients, the infection had a mild course, and only in one, as documented by SCORAD, EASI, and DLQI scores, the condition of the skin deteriorated, and a prolonged positive PCR COVID-19 test was observed. The mechanism of dupilumab action and more evidence for IL13 importance in lung damage caused by SARS-CoV2 suggest a possible explanation for a mild–moderate course of the infection in treated AD patients. Based on current knowledge, there is evidence to continue dupilumab treatment in AD patients with mild–moderate COVID-19; however, careful assessment is needed for each patient.

show abstract

Dupilumab in atopic dermatitis, a protocol for SARS‐COV‐ 2‐infected patients

Cited by 8 publications

References 8 publications

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients

COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review

Contact Info

Product

Resources

About